IUC26509-87

Abstract Code: IUC26509-87   Real-World Effectiveness and Safety of Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma Zeb 1 (1) Heartland Hospital, University Hospital Birmingham – United Kingdom   Background: Enfortumab vedotin...

IUC26698-96

Abstract Code: IUC26698-96   Durvalumab + BCG therapy in BCG-naïve, high-risk NMIBC: efficacy and safety analyses from POTOMAC Hussain 1, N. Shore 2, H. Nishiyama 3, J. Palou Redorta 4, M. Krawczynski 5, A. Seyitkuliev 6, F. Guerrero-Ramos 7, M. Kato 8, T. Powles...

IUC26696-94

Abstract Code: IUC26696-94    Enfortumab Vedotin Plus Pembrolizumab Outcomes in Advanced Urothelial Cancer: Real-World Data Peroos 1, A. Saeed 1, S. Jenkinson 1, A. Clifford 1, M. Prentice 1, S. Mansukhani 1 (1) Royal Free London NHS Foundation Trust –...

IUC26692-90

Abstract Code: IUC26692-90   Benchmarking Artificial Intelligence Based Clinical Prediction Models for Immune Checkpoint Inhibitor Response and Overall Survival in Bladder Cancer Das 1, B. Gonsalves 1, V. Ravindran 2, Y. Agarwala 3, D. Khanna 4, A. Tiwari 5, A....

IUC26685-92

Abstract Code: IUC26685-92   Characterizing the Immune Landscape of Non-Muscle-Invasive Bladder Cancer Fornarini 1, D. Fenoglio 2, F. Ferrera 2, L. Camporesi 2, A. Lagazio 3, F. Lo Iacono 4, T. Altosole 4, N. Piol 5, M. Cremante 1, M. Martiriggiano 6, P. Traverso...

IUC26683-90

Abstract Code: IUC26683-90   BlAdder Cancer Circulating biomarkers after treatment exposUre for early detection of relapse: The BACCUS study Mills 1, A. Bertocchi 2, P. Rescigno 3, J. Frew 4, R. Chandler 4, X. Jiang 4, L. Hogarth 4, M. Mukhiya 4, V. Conteduca 5,...
error: Content is protected !!